Product
PTC+Pertuzumab
1 clinical trial
2 indications
Indication
Breast CancerIndication
HER2-positiveClinical trial
Optimizing Neoadjuvant Systemic Treatment for HER2 Positive Breast Cancer - the TRAIN-2 StudyStatus: Active (not recruiting), Estimated PCD: 2018-12-01